Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;15(1):90-93.
doi: 10.4306/pi.2018.15.1.90. Epub 2018 Jan 16.

Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette's Disorder with Clonidine Extended Release

Sung Woo Joo  1 , Hyo-Won Kim  1
Affiliations

Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette's Disorder with Clonidine Extended Release

Sung Woo Joo et al. Psychiatry Investig. 2018 Jan.

Abstract

We aimed to assess the effectiveness and safety of clonidine extended release (ER) treatment in Korean youth with ADHD and/or Tourette's disorder. We retrospectively reviewed the medical records of 29 children and adolescents treated with clonidine ER. The effectiveness were retrospectively measured at baseline and after 4 and 12 weeks based on the Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores. Safety was evaluated at each visit based on spontaneous reports from the subjects or from their parents/guardians. Significant decreases in the CGI-S scores for both ADHD (F=23.478, p<0.001, partial η2=0.540) and tic symptoms (F=15.137, p<0.001, partial η2=0.443) were noted over 12 weeks. The most common adverse event was somnolence (n=9, 31.0%) and life-threatening adverse effects were not observed. Our results provide preliminary evidence for the effectiveness and safety of clonidine ER.

Keywords: ADHD; Clonidine extended release; Tourette's disorder.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Mean values and confidence intervals of the Clinical Global Impressions-Severity (CGI-S) scores. (A) ADHD and (B) tic symptoms. *p<0.05, **p<0.001. ADHD: attention-deficit/hyperactivity disorder.
See this image and copyright information in PMC

References

    1. Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014;53:153–173. - PubMed
    1. Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53:174–187. - PubMed
    1. Faraone SV. Using Meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T. 2009;34:678–694. - PMC - PubMed
    1. Ganos C, Martino D. Tics and tourette syndrome. Neurol Clin. 2015;33:115–136. - PubMed
    1. Jiao F, Zhang X, Zhang X, Wang J. Clinical observation on treatment of Tourette syndrome in Chinese children by clonidine adhesive patch. Eur J Paediatr Neurol. 2016;20:80–84. - PubMed

LinkOut - more resources